This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human IL-27 Ra / TCCR Protein, Fc Tag
catalog :
ILA-H5254
quantity :
100 ug, 1 mg
price :
250 USD, 1500 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
ILA-H5254
product name :
Human IL-27 Ra / TCCR Protein, Fc Tag
quantity :
100 ug, 1 mg
price :
250 USD, 1500 USD
quantity & price :
$250/100ug,$1500/1mg (250ug × 4)
target :
IL-27 Ra
host species :
Human
By Tag :
Fc Tag
Research :
For Research Use Only
Source :
Human IL-27 Ra, Fc Tag (ILA-H5254) is expressed from human 293 cells (HEK293). It contains AA Gln 33 - Arg 514 (Accession # AAH28003).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>95% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human IL-27 Ra, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Formulation :
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
Interleukin-27 receptor subunit alpha ( IL27RA) is also known as Cytokine receptor WSX-1, Cytokine receptor-like 1, Type I T-cell cytokine receptor (TCCR), ZcytoR1, IL27RA belongs to the type I cytokine receptor family and type 2 subfamily. IL27RA contains three fibronectin type-III domains. IL27RA is highly expressed in lymphoid tissues such as spleen, lymph nodes and peripheral blood leukocytes. IL27RA is receptor for IL27, but requires IL6ST/gp130 to mediate signal transduction in response to IL27. IL27RA involved in the regulation of Th1-type immune responses. IL27RA also appears to be involved in innate defense mechanisms.
References :
(1) Sprecher C.A., et al., 1998, Biochem. Biophys. Res. Commun. 246:82-90.
(2) Chen Q., et al., 2000, Nature 407:916-920.
(3) Pflanz S., et al., 2004, J. Immunol. 172:2225-2231.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments